UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 276

Sortiert nach

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine

Seminars in oncology, 1999-04, Vol.26 (2 Suppl 7), p.3

Capizzi, R L

1999

Link zum Volltext

Verfügbarkeit prüfen

Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects

Seminars in oncology, 1999-04, Vol.26 (2 Suppl 7), p.72

Capizzi, R L

1999

Link zum Volltext

Verfügbarkeit prüfen

Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors

Leukemia, 1998-10, Vol.12 (10), p.1596-1602

1998

Link zum Volltext

Verfügbarkeit prüfen

Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity

Seminars in oncology, 1996-08, Vol.23 (4), p.58-63

1996

Link zum Volltext

Verfügbarkeit prüfen

Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained

European journal of cancer (1990), 1997-09, Vol.33 (10), p.1693-1698

1997

Link zum Volltext

Verfügbarkeit prüfen

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®)

European journal of cancer (1990), 1996, Vol.32, p.S5-S16

Capizzi, R.L.

1996

Link zum Volltext

Verfügbarkeit prüfen

Cutaneous manifestations in celiac disease

World journal of gastroenterology : WJG, 2006-02, Vol.12 (6), p.843

2006

Link zum Volltext

Verfügbarkeit prüfen

Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (ethyol) : clinical experiences

Seminars in oncology, 1994-10, Vol.21 (5), p.8-15

CAPIZZI, R. L

1994

Link zum Volltext

Verfügbarkeit prüfen

Protection of Normal Tissue from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine: Clinical Experiences

European journal of cancer (1990), 1995, Vol.31, p.S8-S13

1995

Link zum Volltext

Verfügbarkeit prüfen

The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer

Journal of clinical oncology, 1991-03, Vol.9 (3), p.371-380

1991

Link zum Volltext

Verfügbarkeit prüfen

Amifostine improves the antileukemic therapeutic index of mafosfamide : implications for bone marrow purging

Blood, 1995-10, Vol.86 (7), p.2849-2855

1995

Link zum Volltext

Verfügbarkeit prüfen

Chemoprotective and radioprotective effects of amifostine : An update of clinical trials

International journal of hematology, 2000-12, Vol.72 (4), p.425-435

2000

Link zum Volltext

Verfügbarkeit prüfen

Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies

Seminars in oncology, 1996-08, Vol.23 (4 Suppl 8), p.2

Capizzi, R

1996

Link zum Volltext

Verfügbarkeit prüfen

Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells

The Journal of clinical investigation, 1987-02, Vol.79 (2), p.380-387

1987

Link zum Volltext

Verfügbarkeit prüfen

Amifostine‐mediated protection of normal bone marrow from cytotoxic chemotherapy

Cancer, 1993-12, Vol.72 (S11), p.3495-3501

1993

Link zum Volltext

Verfügbarkeit prüfen

Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse : Preliminary results

Seminars in oncology, 1996-08, Vol.23 (4), p.35-39

1996

Link zum Volltext

Verfügbarkeit prüfen

Clinical status and optimal use of amifostine

Oncology (Williston Park, N.Y.), 1999-01, Vol.13 (1), p.47

Capizzi, R L

1999

Link zum Volltext

Verfügbarkeit prüfen

1-β-D-arabinofuranosylcytosine-diphosphate-choline is formed by the reversal of cholinephosphotransferase and not via cytidylyltransferase

Cancer research (Chicago, Ill.), 1992-07, Vol.52 (14), p.3886-3891

1992

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Poor Risk Acute Leukemia With Sequential High-Dose ARA-C and Asparaginase

Blood, 1984-03, Vol.63 (3), p.694-700

1984

Link zum Volltext

Verfügbarkeit prüfen

WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells

European journal of cancer (1990), 1996, Vol.32, p.S17-S20

1996

Link zum Volltext

Verfügbarkeit prüfen

Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia

Journal of clinical oncology, 1983-12, Vol.1 (12), p.763-771

1983

Link zum Volltext

Verfügbarkeit prüfen

Recent Developments and Emerging Options: The Role of Amifostine as a Broad-Spectrum Cytoprotective Agent

Seminars in oncology, 1999-04, Vol.26 (2), p.1-2

CAPIZZI, Robert L

1999

Link zum Volltext

Verfügbarkeit prüfen

Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study

Journal of clinical oncology, 1988-03, Vol.6 (3), p.499-508

1988

Link zum Volltext

Verfügbarkeit prüfen

Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association

Journal of clinical oncology, 1988-07, Vol.6 (7), p.1098-1106

1988

Link zum Volltext

Verfügbarkeit prüfen

1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats

Stroke (1970), 1999-09, Vol.30 (9), p.1907-1915

1999

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 276

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(232)
Mit Volltextzugriff
(210)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(187)
Humans
(167)
Life Sciences & Biomedicine
(155)
Female
(98)
Oncology
(88)
Male
(86)
Biological And Medical Sciences
(80)
Medical Sciences
(77)
Middle Aged
(74)
Adult
(67)
Pharmacology. Drug Treatments
(57)
Animals
(51)
Aged
(47)
Antineoplastic Agents
(43)
Chemotherapy
(31)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(30)
Mice
(29)
Cytarabine - Administration & Dosage
(26)
Child
(23)
Physical Sciences
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(21)
Seminars In Oncology
(19)
Cancer Research
(16)
Cancer
(9)
Cancer Treatment Reports
(8)
Blood
(7)
Cancer Chemotherapy And Pharmacology
(7)
European Journal Of Cancer
(7)
Investigational New Drugs
(7)
Leukemia
(7)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine

Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects

Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors

Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity

Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®)

Cutaneous manifestations in celiac disease

Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (ethyol) : clinical experiences

Protection of Normal Tissue from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine: Clinical Experiences

The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer

Amifostine improves the antileukemic therapeutic index of mafosfamide : implications for bone marrow purging

Chemoprotective and radioprotective effects of amifostine : An update of clinical trials

Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies

Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells

Amifostine‐mediated protection of normal bone marrow from cytotoxic chemotherapy

Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse : Preliminary results

Clinical status and optimal use of amifostine

1-β-D-arabinofuranosylcytosine-diphosphate-choline is formed by the reversal of cholinephosphotransferase and not via cytidylyltransferase

Treatment of Poor Risk Acute Leukemia With Sequential High-Dose ARA-C and Asparaginase

WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells

Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia

Recent Developments and Emerging Options: The Role of Amifostine as a Broad-Spectrum Cytoprotective Agent

Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study

Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association

1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats

Suchergebnisse filtern